Crestor vs Amlodipine: Side-Effect Profile Head-to-Head

Why These Two Drugs Are Compared

Rosuvastatin and amlodipine address overlapping patient populations but different physiological targets. They are not interchangeable. A patient with hypertension and dyslipidemia may take both simultaneously, and clinicians need to distinguish which drug is causing a given side effect when symptoms emerge.

The comparison matters most in three clinical scenarios: patients newly prescribed both agents who develop an adverse effect within weeks of initiation, patients with borderline indications weighing risk-benefit for adding a second cardiovascular medication, and patients who attribute a symptom to one drug when the other is more likely responsible. The JUPITER trial (N=17,802) established rosuvastatin 20 mg's cardiovascular benefit in primary prevention [1], while ASCOT-BPLA (N=19,257) demonstrated amlodipine 5-10 mg's superiority over atenolol-based therapy for blood pressure management with cardiovascular protection [2]. Both trials collected extensive safety data that inform this comparison.

The 2018 ACC/AHA cholesterol guidelines recommend statins as first-line therapy for atherosclerotic cardiovascular disease risk reduction [3]. The 2017 ACC/AHA hypertension guidelines list amlodipine among preferred first-line antihypertensives [4]. Neither guideline positions these drugs as alternatives to each other.

Rosuvastatin: Complete Side-Effect Profile

Musculoskeletal complaints dominate rosuvastatin's tolerability picture. Myalgia without CK elevation affects 5-10% of statin users across all formulations, though the STOMP trial (N=420) found that statin-treated patients had no statistically significant increase in muscle pain versus placebo over 6 months, suggesting nocebo effects inflate real-world reporting [5].

True statin-associated muscle symptoms (SAMS) with confirmed CK elevation above 4x the upper limit of normal occur in approximately 1 in 1,000 patients. Rhabdomyolysis is rarer still. The FDA's post-marketing surveillance data show rhabdomyolysis rates below 0.01% for rosuvastatin at approved doses [6]. Risk factors include advanced age, renal impairment, hypothyroidism, and concurrent use of CYP3A4 inhibitors (though rosuvastatin uses CYP2C9, giving it fewer drug interactions than atorvastatin or simvastatin).

Hepatic effects are the second concern. Transaminase elevations above 3x the upper limit of normal occur in 0.2-0.4% of patients on rosuvastatin 20-40 mg [7]. The 2012 FDA guidance removed the requirement for routine liver function monitoring, noting that serious liver injury from statins is idiosyncratic and not predicted by transaminase screening.

The diabetes signal from JUPITER drew significant attention. Among 17,802 participants randomized to rosuvastatin 20 mg or placebo over median 1.9 years, 270 cases of physician-reported diabetes occurred in the rosuvastatin group versus 216 in placebo (HR 1.25 to 95% CI 1.05-1.49) [1]. A subsequent meta-analysis by Sattar et al. (N=91,140 across 13 trials) confirmed a 9% increased risk of incident diabetes with statin therapy, translating to one additional diabetes case per 255 patients treated for 4 years [8].

Other reported effects include headache (2-4%), gastrointestinal disturbance (2-3%), proteinuria at the 40 mg dose (seen more with rosuvastatin than other statins, though typically tubular and benign), and cognitive complaints. The HOPE-3 trial (N=12,705) found no significant cognitive decline with rosuvastatin 10 mg over 5.6 years versus placebo [9].

Amlodipine: Complete Side-Effect Profile

Peripheral edema is amlodipine's signature adverse effect. It is dose-dependent and mechanistic, not allergic. Amlodipine dilates precapillary arterioles without matching venodilation, creating increased capillary hydrostatic pressure and fluid transudation into interstitial tissue. At 5 mg, edema incidence is approximately 3%. At 10 mg, it reaches 10.8% in the prescribing information's pooled clinical trial data [10].

This edema responds poorly to diuretics because it is not volume-mediated. The most effective pharmacological countermeasure is adding an ACE inhibitor or ARB, which dilates post-capillary venules and restores the capillary pressure gradient. The ACCOMPLISH trial demonstrated that amlodipine combined with benazepril reduced edema rates compared to amlodipine alone while maintaining superior cardiovascular outcomes versus hydrochlorothiazide plus benazepril [11].

Flushing and warmth affect 2-4% of patients and share the vasodilatory mechanism. Dizziness occurs in 1-3%. Palpitations and tachycardia are less common (under 2%) because amlodipine's long half-life (30-50 hours) produces gradual plasma level changes that minimize reflex sympathetic activation.

Gingival hyperplasia is a class effect of dihydropyridine calcium channel blockers. Prevalence estimates range from 1.7% to 3.3% with amlodipine [12]. It typically develops after 1-3 months of use and reverses within weeks of discontinuation. Good oral hygiene reduces but does not eliminate risk.

Unlike short-acting nifedipine (which raised safety concerns in the 1990s), amlodipine has demonstrated cardiovascular safety in multiple large outcomes trials. ALLHAT (N=33,357) showed amlodipine-based therapy had equivalent coronary event rates to chlorthalidone and lisinopril, though heart failure rates were slightly higher with amlodipine (RR 1.38 vs chlorthalidone) [13].

Direct Safety Comparison: Discontinuation and Tolerability

No randomized trial has directly compared rosuvastatin versus amlodipine for tolerability endpoints. The comparison requires cross-trial interpretation with appropriate caveats about differing populations, follow-up durations, and adverse event definitions.

In JUPITER, 3.7% of rosuvastatin patients discontinued due to adverse events versus 3.5% of placebo patients over 1.9 years [1]. The near-identical rates suggest rosuvastatin's excess discontinuation burden is minimal in a clinical trial setting. Real-world adherence data tell a different story: approximately 50% of statin prescriptions are abandoned within 12 months in pharmacy claims databases [14].

In ASCOT-BPLA, the amlodipine-based arm had lower overall discontinuation than the atenolol-based arm, though peripheral edema specifically drove 2-3% of patients to switch therapy. The 5.5-year trial duration provides longer exposure data than JUPITER's 1.9 years [2].

Dr. Steven Nissen, Cleveland Clinic's cardiovascular medicine chairman, has stated regarding statin tolerability: "The nocebo effect accounts for the majority of muscle symptoms attributed to statins. When patients don't know they're taking a statin, symptom rates are nearly identical to placebo" [15].

A practical distinguishing factor: rosuvastatin's adverse effects tend to be subjective (muscle aching, fatigue, cognitive fog) and difficult to verify objectively. Amlodipine's primary adverse effect (edema) is visible and measurable. This difference influences clinical decision-making because patients and clinicians can readily identify amlodipine-related edema, while statin-attributed myalgia requires more diagnostic uncertainty management.

Metabolic Effects: Glucose, Lipids, and Weight

Rosuvastatin's impact on glucose metabolism is clinically relevant. Beyond the new-onset diabetes signal, the JUPITER data showed that patients who developed diabetes on rosuvastatin tended to have baseline risk factors (impaired fasting glucose, metabolic syndrome, BMI >30) that predicted eventual diabetes regardless of statin exposure [1]. The Endocrine Society's 2015 position statement concluded that cardiovascular benefits of statins outweigh diabetes risk in all but the lowest-risk patients [16].

Amlodipine is metabolically neutral. It does not affect glucose tolerance, insulin sensitivity, or lipid profiles. This metabolic neutrality distinguished it from older antihypertensives (beta-blockers, thiazide diuretics) in ASCOT-BPLA, where the amlodipine-based regimen was associated with 30% fewer new diabetes cases compared to the atenolol-based regimen [2]. The 2017 ACC/AHA guideline authors noted: "Calcium channel blockers and ACE inhibitors/ARBs are preferred in patients at high metabolic risk because they avoid the adverse glucose effects seen with thiazides and beta-blockers" [4].

Weight gain is not a direct effect of either drug, though amlodipine-related edema can increase scale weight by 1-3 kg without representing true adiposity gain. Rosuvastatin does not cause weight change in controlled trials.

Drug Interactions and Combination Safety

Rosuvastatin has fewer CYP450-mediated drug interactions than atorvastatin, simvastatin, or lovastatin because it is primarily metabolized by CYP2C9 with minimal CYP3A4 involvement [7]. Clinically important interactions include:

Cyclosporine increases rosuvastatin exposure 7-fold (contraindicated combination). Gemfibrozil doubles rosuvastatin exposure (dose cap at 10 mg). Atazanavir/ritonavir increases exposure 3-fold (dose cap at 10 mg). Warfarin INR may increase modestly (monitoring recommended at initiation).

Amlodipine is metabolized by CYP3A4. Strong CYP3A4 inhibitors (clarithromycin, itraconazole, ritonavir) increase amlodipine levels and may potentiate hypotension and edema. Simvastatin's FDA label specifically caps the dose at 20 mg when combined with amlodipine due to increased myopathy risk from this interaction [17]. Rosuvastatin does not share this interaction with amlodipine, making the rosuvastatin-amlodipine combination pharmacokinetically cleaner than simvastatin-amlodipine.

For patients requiring both a statin and amlodipine, rosuvastatin is pharmacokinetically preferable to simvastatin or lovastatin due to the absence of CYP3A4-mediated interaction amplification.

Special Populations: Age, Sex, and Renal Function

Elderly patients (over 75): Rosuvastatin's myalgia incidence increases modestly with age, partly due to declining renal function and decreased muscle mass. The FDA recommends starting at 5 mg in Asian patients due to higher rosuvastatin bioavailability in pharmacokinetic studies [6]. Amlodipine clearance decreases with age, and the prescribing information recommends initiating at 2.5 mg in elderly patients, though 5 mg is commonly used [10].

Women: The JUPITER trial enrolled 6,801 women and found consistent cardiovascular benefit. Women reported numerically higher rates of myalgia across statin trials generally, though sex-stratified discontinuation rates in JUPITER were not significantly different [1]. Amlodipine's edema disproportionately affects women: post-marketing data suggest women experience peripheral edema at roughly 1.5-2x the rate of men at equivalent doses [10].

Renal impairment: Rosuvastatin 40 mg is contraindicated when eGFR falls below 30 mL/min/1.73m². Lower doses (5-20 mg) may be used with monitoring [7]. Amlodipine requires no dose adjustment in renal impairment because it is eliminated hepatically with negligible renal excretion. For patients with CKD stage 4-5, amlodipine's pharmacokinetic simplicity offers an advantage.

Hepatic impairment: Both drugs are contraindicated in active liver disease. Rosuvastatin is specifically contraindicated when transaminases exceed 3x the upper limit persistently [7]. Amlodipine's half-life extends to 60+ hours in severe cirrhosis, requiring dose reduction [10].

When Patients Take Both: Identifying the Culprit

The clinical scenario of a patient on both rosuvastatin and amlodipine who develops a new symptom requires systematic evaluation. Ankle swelling appearing 2-4 weeks after starting amlodipine is almost certainly drug-related. Muscle pain developing within weeks of rosuvastatin initiation warrants CK measurement, but the clinician should consider whether the symptom preceded therapy (baseline myalgia is common in middle-aged adults with sedentary lifestyles).

A structured dechallenge-rechallenge approach works best. Hold the suspected drug for 2-4 weeks. If symptoms resolve, consider reintroduction at a lower dose or on alternate days (for rosuvastatin) or with an added ACE inhibitor (for amlodipine edema). The N-of-1 crossover methodology used in the StatinWISE trial (N=200) demonstrated that blinded statin rechallenge reproduced muscle symptoms at rates no higher than placebo in most participants [18].

Fatigue attributed to statins may alternatively represent amlodipine-induced hypotension in patients with lower baseline blood pressure. Checking orthostatic vitals can differentiate the mechanism.

Long-Term Safety: 5+ Years of Exposure

Long-term rosuvastatin safety data extend through HOPE-3's 5.6-year median follow-up and multiple post-marketing surveillance periods exceeding 15 years since approval [9]. No new safety signals have emerged beyond those identified in the first 5 years of use. Hemorrhagic stroke risk (a theoretical concern from very low LDL levels) was not confirmed in JUPITER or subsequent analyses [1].

Amlodipine has post-marketing data spanning over 30 years since its 1992 FDA approval. ALLHAT's 8-year extended follow-up confirmed long-term cardiovascular safety [13]. No evidence links amlodipine to cancer, cognitive decline, or increased mortality with prolonged use.

Both drugs are classified as pregnancy category X (rosuvastatin) and category C (amlodipine). Neither should be initiated during pregnancy planning.

Rosuvastatin 20 mg combined with amlodipine 5 mg in a patient with both dyslipidemia and hypertension produces cardiovascular risk reduction exceeding either agent alone, with expected adverse-event incidence of approximately 5-10% for myalgia, 3% for peripheral edema, and under 1% for clinically significant laboratory abnormalities requiring dose adjustment.